Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.
Marín F, Fernández MS, Barón-Esquivias G, Barrios V, Lekuona I, Pérez-Cabeza AI, Masjuan J, Del Vigo ER, Vázquez Rodríguez JM, Freixa-Pamias R, Schilling VR, Arribas F, Priu CR, Sánchez MA. Marín F, et al. J Comp Eff Res. 2023 Mar;12(3):e220049. doi: 10.57264/cer-2022-0049. Epub 2023 Feb 7. J Comp Eff Res. 2023. PMID: 36749006 Free PMC article.
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M, Anguita Sánchez M, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Pérez-Cabeza AI, Ureña I, Vázquez Rodríguez JM, Rafols Priu C, Marin F. Sanmartín Fernández M, et al. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. Cardiol J. 2022. PMID: 35621092 Free PMC article.
BACKGROUND: The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE. METHODS: This was a post-authorization and observational study of AF adults treated with r …
BACKGROUND: The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivarox …